<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02295163</url>
  </required_header>
  <id_info>
    <org_study_id>NL46979.091.13</org_study_id>
    <nct_id>NCT02295163</nct_id>
  </id_info>
  <brief_title>Stellate Ganglion Block for Hot Flushes in Men Treated With ADT</brief_title>
  <official_title>Short-term Efficacy of Stellate Ganglion Block in Men to Reduce Hot Flushes Related to Androgen Deprivation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rijnstate Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Androgen deprivation therapy (ADT) is widely used as standard therapy in the treatment of
      locally advanced and metastatic prostate cancer. Hot flushes and night sweats are one of the
      main side-effects of ADT. There are no successful and well-tolerable treatment options
      available. A possible treatment for hot flushes is stellate-ganglion block (SGB), used as a
      means of interrupting parts of the sympathetic nervous system involved in temperature
      regulation.

      Objective of this study:

      To assess the short-term efficacy of stellate ganglion block on hot flush reduction versus
      sham procedure
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Androgen deprivation therapy (ADT) is widely used as standard therapy in the treatment of
      locally advanced and metastatic prostate cancer. Hot flushes and night sweats are one of the
      main side-effects of ADT. There are no successful and well-tolerable treatment options
      available. A possible treatment for hot flushes is stellate-ganglion block (SGB), used as a
      means of interrupting parts of the sympathetic nervous system involved in temperature
      regulation.

      Objective of this study
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hot flush score</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Sham procedure</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>injection of NACL 0,9% in the stellate ganglion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stellate ganglion block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection of Bupivacaine 0,5% in the stellate ganglion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stellate ganglion block</intervention_name>
    <description>7 ml of 0.5% bupivacaine will subsequently be injected next to the stellate ganglion to produce a sympathetic block.</description>
    <arm_group_label>Stellate ganglion block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham procedure</intervention_name>
    <description>7 ml of 0.9 % sodium chloride will subsequently be injected next to the stellate ganglion</description>
    <arm_group_label>Sham procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Age: &gt;18 years

          -  Mean daily flush frequency of 10 or more and a hot flush score of 15 or more

          -  Treatment with ADT because of prostate cancer

          -  Absence of any other cause of flushing

        Exclusion Criteria:

          -  Use of medication that affects flushing: oestrogens, progestogens, clonidine,
             naloxone, paroxetine, fluoxetine, venlafaxine, gabapentin, luteinizing
             hormone-releasing hormone receptor antagonist

          -  Still receiving chemotherapy of radiotherapy

          -  Psychiatric disease

          -  Any unstable concurrent disease

          -  Allergic reactions against bupivacaine or contrast media.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jw. kallewaard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rijnstate Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Willem Kallewaard, MD</last_name>
    <phone>0031622412029</phone>
    <email>jkallewaard@rijnstate.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>K sax</last_name>
    <phone>0031263788888</phone>
    <email>ksax@rijnstate.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.W Kallewaard, MD</last_name>
      <phone>0031622412029</phone>
      <email>jkallewaard@rijnstate.nl</email>
    </contact>
    <contact_backup>
      <last_name>K Sax, MD</last_name>
      <phone>0031263788888</phone>
      <email>ksax@rijnstate.nl</email>
    </contact_backup>
    <investigator>
      <last_name>J.W. Kallewaard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>K Sax, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>jw Geurts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rijnstate Hospital</investigator_affiliation>
    <investigator_full_name>Jan Willem Kallewaard</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Stellate ganglion block</keyword>
  <keyword>hot flushes</keyword>
  <keyword>androgen deprivation therapy</keyword>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Ganglion Cysts</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

